Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate resistant prostate cancer (mCRPC): Cohort A of the phase 1b/2 KEYNOTE-365 study.

被引：3
|
作者：
Yu, Evan Y.
Massard, Christophe
Retz, Margitta
Tafreshi, Ali
Carles, Joan
Hammerer, Peter
Fong, Peter C. C.
Shore, Neal D.
Joshua, Anthony M.
Linch, Mark David
Gurney, Howard
Romano, Emanuela
Augustin, Marinela
Piulats, Josep M.
Wu, Helen
Schloss, Charles
Poehlein, Christian Heinrich
De Bono, Johann S.
机构：
[1] Univ Washington, Seattle, WA 98195 USA
[2] Gustave Roussy Canc Campus, Villejuif, France
[3] Univ Paris Sud, Villejuif, France
[4] Tech Univ Munich, Rechts Isar Univ Hosp, Munich, Germany
[5] Univ Wollongong, Wollongong, NSW, Australia
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Acad Hosp Braunschweig, Braunschweig, Germany
[8] Auckland City Hosp, Auckland, New Zealand
[9] Carolina Urol Res Ctr, Myrtle Beach, SC USA
[10] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[11] UCL, Inst Canc, London, England
[12] Macquarie Univ Hosp, Sydney, NSW, Australia
[13] Inst Curie, Paris, France
[14] Klinikum Nurnberg, Nurnberg, Germany
[15] Catalan Canc Inst, Barcelona, Spain
[16] Merck & Co Inc, Kenilworth, NJ USA
[17] Royal Marsden Hosp, London, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.5027
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5027
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
  • [22] Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
    Yu, Evan Y.
    Kolinsky, Michael P.
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Appleman, Leonard J.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    Bogemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Linch, Mark
    Sridhar, Srikala
    Conter, Henry J.
    Laguerre, Brigitte
    Massard, Christophe
    Li, Xin Tong
    Schloss, Charles
    Poehlein, Christian H.
    de Bono, Johann S.
    EUROPEAN UROLOGY, 2022, 82 (01) : 22 - 30
  • [23] Pembrolizumab and Enzalutamide in Patients with Abiraterone Acetate-Pretreated Metastatic Castration-Resistant Prostate Cancer: Cohort C of the Phase 1b/2 KEYNOTE-365 Study
    Yu, Evan Y.
    Berry, William R.
    Gurney, Howard
    Retz, Margitta
    Conter, Henry J.
    Laguerre, Brigitte
    Fong, Peter C. C.
    Ferrario, Cristiano
    Todenhofer, Tilman
    Gravis, Gwenaelle
    Piulats, Josep M.
    Emmenegger, Urban
    Shore, Neal D.
    Romano, Emanuela
    Mourey, Loic
    Li, Xin Tong
    Poehlein, Christian H.
    Schloss, Charles
    Appleman, Leonard J.
    Bono, Johann S. de
    EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03): : 509 - 518
  • [24] Phase 1b/2 study of pembrolizumab (pembro) plus platinum/etoposide and platinum/etoposide for neuroendocrine metastatic prostate cancer (NEPC): KEYNOTE-365 cohort I.
    Yu, Evan Y.
    Joshua, Anthony M.
    Kramer, Gero
    Shore, Neal D.
    Hu, Haixia
    Poehlein, Christian Heinrich
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS249 - TPS249
  • [25] KEYNOTE-365 cohort D: phase 1b/2 study of pembrolizumab plus abiraterone acetate and prednisone in metastatic castration-resistant prostate cancer
    Appleman, Leonard
    Piulats, Josep
    Mar, Nataliya
    Arranz, Jose
    Joshua, Anthony
    Mayer, Tina
    Shore, Neal
    Wu, Haiyan
    Schloss, Charles
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [26] Pembrolizumab (pembro) plus enzalutamide (enza) in patients (pts) with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort C efficacy, safety, and biomarker results.
    Conter, Henry Jacob
    Shore, Neal D.
    Berry, William R.
    Fong, Peter C. C.
    Rodriguez, Jose Maria M. Piulats
    Appleman, Leonard Joseph
    Todenhoefer, Tilman
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Gurney, Howard
    Retz, Margitta
    Romano, Emanuela
    Mourey, Loic
    De Bono, Johann S.
    Kam, Audrey E.
    Emmenegger, Urban
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [27] Update on KEYNOTE-199, cohorts 1-3: Pembrolizumab (pembro) for docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Piulats, Josep M.
    Gross-Goupil, Marine
    Goh, Jeffrey C.
    Vaishampayan, Ulka N.
    De Wit, Ronald
    Alanko, Tuomo
    Fukasawa, Satoshi
    Tabata, Kenichi
    Feyerabend, Susan
    Berger, Raanan
    Wu, Helen
    Kim, Jeri
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [28] KEYNOTE-365 cohort B: Pembrolizumab (pembro) plus docetaxel and prednisone in abiraterone (abi) or enzalutamide (enza)-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC)-New data after an additional 1 year of follow-up.
    Appleman, Leonard Joseph
    Kolinsky, Michael Paul
    Berry, William R.
    Retz, Margitta
    Mourey, Loic
    Piulats, Josep M.
    Romano, Emanuela
    Gravis, Gwenaelle
    Gurney, Howard
    De Bono, Johann S.
    Boegemann, Martin
    Emmenegger, Urban
    Joshua, Anthony M.
    Massard, Christophe
    Sridhar, Srikala S.
    Conter, Henry Jacob
    Li Xin Tong
    Schloss, Charles
    Poehlein, Christian Heinrich
    Yu, Evan Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (06)
  • [29] Association between homologous recombination repair mutations and response to pembrolizumab (pembro) plus olaparib (ola) in metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A biomarker analysis
    Yu, E.
    Piulats, J. M.
    Gravis, G.
    Fong, P.
    Todenhoefer, T.
    Laguerre, B.
    Arranz, J.
    Oudard, S.
    Massard, C.
    Stoeckle, M.
    Nordquist, L. T.
    Carles, J.
    Huang, M.
    Li, Y.
    Qiu, P.
    Poehlein, C. H.
    Schloss, C.
    de Bono, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S387 - S387
  • [30] PEMBROLIZUMAB plus LENVATINIB IN PATIENTS WITH ADENOCARCINOMA METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) OR TREATMENT-EMERGENT NEUROENDOCRINE MCRPC: PHASE 1B/2 KEYNOTE-365 COHORTS E/F
    Kramer, Gero
    Shore, Neal
    Joshua, Anthony
    Li, Xin Tong
    Poehlein, Christian
    Schloss, Charles
    De Bono, Johann
    Yu, Evan
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A449 - A449
12345